INmune Bio, Inc. (INMB) Income Statement
INMB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsINMB revenue and net income
Where INMB's revenue goes
2025Each bar shows an amount and its share of revenue. INMB kept −91,866.0% of revenue as net income.
INMB profit margins
INMB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +257.1% | −48.9% | +35.6% | — |
| Gross profit | +257.1% | −48.9% | +35.6% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
INMB quarterly EPS vs estimates
INmune Bio beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: October 29, 2026 (estimate $-0.18).
INMB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50,000 | $14,000 | $155,000 | $374,000 | $181,000 | $10,916 | $77.7M | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $50,000 | $14,000 | $155,000 | $374,000 | $181,000 | $10,916 | $77.7M | $0 | $0 | $0 |
| Research & development | $20.7M | $33.2M | $20.3M | $17.1M | $20.5M | $5.9M | $3.3M | $1.1M | $435,362 | $101,495 |
| Sales, general & admin | $10.3M | $9.5M | $9.8M | $9.3M | $8.8M | $6.4M | $6.0M | $11.3M | $546,118 | $125,996 |
| Total operating expenses | $30.9M | $42.6M | $29.9M | $26.3M | $29.3M | $12.2M | $7.8M | $12.4M | $981,480 | $227,491 |
| Operating income | −$30.9M | −$42.6M | −$29.7M | −$26.0M | −$29.2M | −$12.2M | −$7.8M | −$12.4M | −$981,000 | −$227,000 |
| Interest income | — | — | — | — | — | — | $77,688 | — | — | — |
| Interest expense | — | — | — | $1.3M | $1.2M | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$45.9M | −$42.1M | −$30.0M | −$27.3M | −$30.3M | −$12.1M | −$7.7M | −$12.4M | −$831,000 | −$277,000 |
| Income taxes | — | — | −$29.7M | $1.3M | $1.2M | −$128,517 | $1.5M | −$161,141 | −$1.1M | −$177,000 |
| Net income | −$45.9M | −$42.1M | −$30.0M | −$28.6M | −$30.3M | −$12.1M | −$7.7M | −$12.4M | −$831,000 | −$277,000 |
| EBITDA | −$45.8M | −$41.5M | −$267,000 | −$27.3M | −$30.3M | −$12.2M | −$7.7M | −$12.4M | $150,480 | −$49,509 |
| EPS (diluted) | −$1.19 | −$2.11 | −$1.67 | −$1.52 | −$1.86 | −$1.01 | −$0.89 | −$1.08 | −$0.07 | −$0.06 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating margin | −61,738.0% | −304,535.7% | −19,187.7% | −6,938.8% | −16,106.6% | −112,016.1% | −10.0% | — | — | — |
| Net margin | −91,866.0% | −300,585.7% | −19,360.0% | −7,659.6% | −16,762.4% | −110,838.8% | −9.9% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $50,000 | $0 | $0 | $0 | $14,000 | $28,000 | $43,000 |
| Cost of revenue | — | $52,000 | $56,000 | $28,000 | — | $0 | — | — | — | $0 | $0 | $0 |
| Gross profit | — | −$52,000 | −$56,000 | −$28,000 | — | $50,000 | — | — | — | $14,000 | $28,000 | $43,000 |
| Research & development | $803,000 | $3.6M | $2.3M | $4.9M | $5.8M | $7.6M | $7.4M | $10.1M | $7.1M | $8.7M | $6.0M | $6.0M |
| Sales, general & admin | $2.3M | $2.2M | $3.1M | $2.7M | $2.3M | $2.3M | $2.0M | $2.3M | $2.8M | $2.3M | $2.4M | $2.6M |
| Total operating expenses | $1.5M | $5.8M | $5.4M | $7.4M | $24.6M | $10.0M | $9.5M | $12.3M | $9.9M | $11.0M | $8.4M | $8.6M |
| Operating income | −$1.5M | −$5.8M | −$5.5M | −$7.4M | −$24.6M | −$9.9M | −$9.5M | −$12.3M | −$9.9M | −$11.0M | −$8.4M | −$8.5M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $113,000 | — |
| Income before taxes | −$1.3M | −$5.4M | −$5.3M | −$6.5M | −$24.5M | −$9.7M | −$9.2M | −$12.1M | −$9.7M | −$11.0M | −$8.4M | −$8.6M |
| Income taxes | — | — | — | — | — | — | — | — | −$9.9M | −$11.0M | $14.8M | −$8.5M |
| Net income | −$1.3M | −$5.4M | −$5.3M | −$6.5M | −$24.5M | −$9.7M | −$9.2M | −$12.1M | −$9.7M | −$11.0M | −$8.4M | −$8.6M |
| EBITDA | −$1.2M | −$5.4M | −$5.2M | −$6.5M | −$8.1M | −$9.7M | −$9.2M | −$12.1M | −$9.7M | −$11.0M | −$8.4M | −$35,000 |
| EPS (diluted) | −$0.05 | −$0.20 | −$0.18 | −$0.24 | −$0.34 | −$0.43 | −$0.40 | −$0.60 | −$0.50 | −$0.61 | −$0.47 | −$0.48 |
| Gross margin | — | — | — | — | — | 100.0% | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating margin | — | — | — | — | — | −19,810.0% | — | — | — | −78,692.9% | −29,925.0% | −19,832.6% |
| Net margin | — | — | — | — | — | −19,478.0% | — | — | — | −78,750.0% | −30,028.6% | −19,914.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in INMB's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
INMB financial results
In fiscal year 2025 (ended December 31, 2025), INmune Bio reported revenue of $0.1 million, up 257.1% from the year before. It had a net loss of $45.9 million, a net profit margin of −91,866.0%. Diluted earnings per share came to −$1.19. Over five years revenue grew at an average rate of 35.6% a year.
See the INMB stock overview for the latest quote and news, or the INMB chart for price history and technical indicators.
INMB income statement FAQ
What is INmune Bio's annual revenue?
INmune Bio reported total revenue of $0.1 million for fiscal year 2025, which ended on December 31, 2025. That was up 257.1% from $0.0 million the previous year.
Is INmune Bio profitable?
No. INmune Bio reported a net loss of $45.9 million in fiscal 2025, a net profit margin of −91,866.0%; its operating margin was −61,738.0%.
What is INmune Bio's gross margin?
INmune Bio's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, INmune Bio kept $100 after the direct cost of its products and services.
How much does INmune Bio spend on research and development?
INmune Bio spent $20.7 million on research and development in fiscal 2025, 41,318.0% of revenue.
How fast is INmune Bio growing?
Revenue grew 35.6% a year on average over the last five fiscal years, from $0.0 million to $0.1 million.
What are INmune Bio's earnings per share?
INmune Bio earned $-1.19 per diluted share in fiscal 2025, compared with $-2.11 a year earlier.
When will INmune Bio report its next earnings?
INmune Bio is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes.
When does INmune Bio's fiscal year end?
INmune Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.